These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34963505)

  • 21. Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia.
    Krieger E; Kudryavtsev A; Sharashova E; Postoev V; Belova N; Shagrov L; Zvedina J; Drapkina O; Kontsevaya A; Shalnova S; Brenn T; Shkolnikov VM; Eggo RM; Leon DA
    Emerg Infect Dis; 2022 Feb; 28(2):463-465. PubMed ID: 35076366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 Seroconversion in Response to Infection and Vaccination: a Time Series Local Study in Brazil.
    Huergo LF; Paula NM; Gonçalves ACA; Kluge CHS; Marins PHSA; Camargo HSC; Sant'Ana TP; Farias LRP; Aldrighi JD; Lima ÊS; Jacotenski GT; Vargas LR; Costa G; Weissheimer KV; Nazário MG; Teixeira KN; Conzentino MS
    Microbiol Spectr; 2022 Aug; 10(4):e0102622. PubMed ID: 35770982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human and novel coronavirus infections in children: a review.
    Rajapakse N; Dixit D
    Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2 Spillback to Wild Coatis in Sylvatic-Urban Hotspot, Brazil.
    Stoffella-Dutra AG; de Campos BH; Bastos E Silva PH; Dias KL; da Silva Domingos IJ; Hemetrio NS; Xavier J; Iani F; Fonseca V; Giovanetti M; de Oliveira LC; Teixeira MM; Lobato ZIP; Ferreira HL; Arns CW; Durigon E; Drumond BP; Alcantara LCJ; de Carvalho MPN; de Souza Trindade G
    Emerg Infect Dis; 2023 Mar; 29(3):664-667. PubMed ID: 36823719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Impact of the Highly Virulent SARS-CoV-2 Gamma Variant on Young Adults in the State of São Paulo: Was It Inevitable?
    Spira B
    Cureus; 2022 Jul; 14(7):e26486. PubMed ID: 35919213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant.
    Quintero AM; Eisner M; Sayegh R; Wright T; Ramilo O; Leber AL; Wang H; Mejias A
    Emerg Infect Dis; 2022 Nov; 28(11):2270-2280. PubMed ID: 36285986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
    Shakiba M; Nazemipour M; Salari A; Mehrabian F; Nazari SSH; Rezvani SM; Ghasempour Z; Heidarzadeh A; Mansournia MA
    Emerg Infect Dis; 2021 Feb; 27(2):636-638. PubMed ID: 33349310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid SARS-CoV-2 Seroprevalence Survey in Central and Western Divisions of Fiji, 2021.
    Curtis SJ; Shah AW; Ratu A; Wilson DJ; Hill PC; Hulcome P; Gaylard C; Faktaufon D; Cabemaiwai T; Rabukawaqa I; Qoriniasi T; Narayan A; Nakalevu S; Romakin P; Tudravu J; Fong J; Walsh N
    Emerg Infect Dis; 2023 Jan; 29(1):226-228. PubMed ID: 36573643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2-Specific Antibodies in Domestic Cats during First COVID-19 Wave, Europe.
    Schulz C; Martina B; Mirolo M; Müller E; Klein R; Volk H; Egberink H; Gonzalez-Hernandez M; Kaiser F; von Köckritz-Blickwede M; Osterhaus A
    Emerg Infect Dis; 2021 Dec; 27(12):3115-3118. PubMed ID: 34695368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil.
    Fintelman-Rodrigues N; da Silva APD; Dos Santos MC; Saraiva FB; Ferreira MA; Gesto J; Rodrigues DAS; Vale AM; de Azevedo IG; Soares VC; Jiang H; Tan H; Tschoeke DA; Sacramento CQ; Bozza FA; Morel CM; Bozza PT; Souza TML
    Emerg Infect Dis; 2021 May; 27(5):1446-1453. PubMed ID: 33797393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections.
    Tober-Lau P; Gruell H; Vanshylla K; Koch WM; Hillus D; Schommers P; Suárez I; Suttorp N; Sander LE; Klein F; Kurth F
    Emerg Infect Dis; 2022 May; 28(5):1050-1052. PubMed ID: 35259088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody cocktail effective against variants of SARS-CoV-2.
    Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC
    J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.
    Petersen MS; Strøm M; Fjallsbak JP; Hansen JL; Larsen S; Eliasen EH; Johansen M; Veyhe AS; Kristiansen MF; Weihe P
    Emerg Infect Dis; 2022 Jan; 28(1):242-244. PubMed ID: 34757895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2 Sequence Analysis during COVID-19 Case Surge, Liberia, 2021.
    Shobayo B; Mishra M; Sameroff S; Petrosov A; Ng J; Gokden A; MaCauley J; Jain K; Renken C; Duworko JT; Badio M; Jallah W; Hensley L; Briese T; Lipkin WI; Mishra N
    Emerg Infect Dis; 2021 Dec; 27(12):3185-3188. PubMed ID: 34708683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New Jersey.
    Mathema B; Chen L; Wang P; Cunningham MH; Mediavilla JR; Chow KF; Luo Y; Zhao Y; Composto K; Zuckerman J; Zody MC; Wilson N; Lee A; Oschwald DM; Liu L; Iketani S; Germer S; Fennessey S; Wang M; Kramer Y; Toole P; Maniatis T; Ho DD; Perlin DS; Kreiswirth BN
    mBio; 2022 Oct; 13(5):e0214122. PubMed ID: 35997285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacajá (Kayapó) indigenous population in the brazilian Amazon.
    Rodrigues EPS; Abreu IN; Lima CNC; da Fonseca DLM; Pereira SFG; Dos Reis LC; Vallinoto IMVC; Guerreiro JF; Vallinoto ACR
    Int J Equity Health; 2021 Jan; 20(1):50. PubMed ID: 33509206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 Variants and Age-Dependent Infection Rates among Household and Nonhousehold Contacts.
    Miyahara R; Tamura K; Kato T; Nakazaki M; Otani K; Ko YK; Kamigaki T; Arima Y; Tani H; Oishi K; Suzuki M
    Emerg Infect Dis; 2023 Aug; 29(8):1648-1650. PubMed ID: 37343546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil.
    Nonaka CKV; Franco MM; Gräf T; de Lorenzo Barcia CA; de Ávila Mendonça RN; de Sousa KAF; Neiva LMC; Fosenca V; Mendes AVA; de Aguiar RS; Giovanetti M; de Freitas Souza BS
    Emerg Infect Dis; 2021 May; 27(5):1522-1524. PubMed ID: 33605869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.